Summa Biotech is a medical biotech company that is founded in 2022 and focuses on developing ground-breaking RNA-based medicines that reverse the damage of ischemic heart disease, which is a leading cause of death worldwide. 

We aim restore damaged heart tissue by eliciting the regeneration of healthy cells and tissues using RNA therapeutics.

Summa Biotech’s strategy is to develop game-changing curative therapies for ischemic heart disease by leveraging academic expertise, cutting-edge disease models and fostering a culture of team excellence.

Summa Biotech

Org chart

Teams

Offices